{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:24:08Z","timestamp":1781216648140,"version":"3.54.1"},"reference-count":24,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: This study aimed to evaluate the prognostic value of the SUVmax\u2013IPI composite score, generated by integrating the maximum standardized uptake value (SUVmax) derived from metastatic 68Ga-PSMA PET\/CT imaging with the inflammatory prognostic index (IPI), in predicting overall survival in patients with metastatic prostate cancer. Materials and Methods: This retrospective, single-center cohort study included 146 patients diagnosed with metastatic prostate adenocarcinoma between 2009 and 2025. Among them, 125 patients with available PET\/CT imaging were included in the SUVmax\u2013IPI analysis. The composite score was calculated by multiplying the metastatic SUVmax value by the IPI. The optimal cut-off value was determined using receiver operating characteristic curve analysis. Overall survival was evaluated using the Kaplan\u2013Meier method and compared using the log-rank test. Independent prognostic factors were identified using multivariable Cox proportional hazards regression analysis with a forward (stepwise) selection approach. Results: Using the predefined cut-off value (82), the median overall survival was 125 months in patients with SUVmax\u2013IPI \u2264 82 and 19 months in those with SUVmax\u2013IPI &gt; 82 (log-rank p = 0.001). In the forward multivariable Cox regression model, SUVmax\u2013IPI &gt; 82 remained independently associated with worse overall survival after adjustment for ALP, AST, PSA nadir, and androgen deprivation modality (hazard ratio [HR]: 7.92; 95% confidence interval [CI]: 2.97\u201321.10; p &lt; 0.001). Conclusions: The SUVmax\u2013IPI composite score, integrating PSMA PET\/CT-derived metabolic tumor activity with systemic inflammatory burden, is independently associated with overall survival in metastatic prostate cancer. These findings suggest that combining metabolic and inflammatory parameters may enhance prognostic stratification beyond conventional clinical and biochemical markers.<\/jats:p>","DOI":"10.3390\/jcm15072655","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:23:17Z","timestamp":1774963397000},"page":"2655","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Value of the SUVmax\u2013IPI Composite Score on Overall Survival in Metastatic Prostate Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1540-3705","authenticated-orcid":false,"given":"Emine","family":"T\u00fcrkmen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, 45047 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atike P\u0131nar","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, 45047 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u015eahbazlar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, 45047 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6zde","family":"M\u00fctevelizade","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Manisa Celal Bayar University, 45047 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, 45047 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: A systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2025.43.16_suppl.5002","article-title":"Prognostic significance of PSA >0.2 after 6\u201312 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry","volume":"43","author":"Ong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: An international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Senn","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Malcher","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75381","DOI":"10.18632\/oncotarget.18856","article-title":"Prognostic role of systemic immune-inflammation index in solid tumors: A systematic review and meta-analysis","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e222010","DOI":"10.1148\/radiol.222010","article-title":"A prognostic risk score for prostate cancer based on PSMA PET-derived organ-specific tumor volumes","volume":"307","author":"Seifert","year":"2023","journal-title":"Radiology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_17","first-page":"455","article-title":"Inflammation in prostate cancer progression and therapeutic targeting","volume":"4","author":"Stark","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kolk\u0131ran, N., Erdo\u011fan, A.P., \u015eahbazlar, M., Ta\u015f, S., Do\u011fu, G.G., Canaslan, K., \u00dcnek, \u0130.T., Demirk\u0131ran, \u00d6., Demir, B., and Tek\u00fcst\u00fcn, G.N. (2025). SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32100566"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e20343","DOI":"10.7717\/peerj.20343","article-title":"IPI score as a new prognostic index in extensive stage small cell lung cancer","volume":"13","author":"Ekinci","year":"2025","journal-title":"PeerJ"},{"key":"ref_20","first-page":"5101","article-title":"A new inflammatory prognostic index based on C-reactive protein, the neutrophil-to-lymphocyte ratio, and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases","volume":"17","author":"Dirican","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","article-title":"New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide","volume":"47","author":"Rosar","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pros.23465","article-title":"Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients","volume":"78","author":"Fan","year":"2018","journal-title":"Prostate"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mitsui, Y., Yamabe, F., Hori, S., Uetani, M., Aoki, H., Sakurabayashi, K., Okawa, M., Kobayashi, H., Nagao, K., and Nakajima, K. (2023). Combination of C-reactive protein\/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1162820"},{"key":"ref_24","unstructured":"European Association of Urology (2025). EAU Guidelines on Prostate Cancer 2025, EAU Guidelines Office."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2655\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:23:12Z","timestamp":1775103792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072655"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072655","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}